Related Experiment Video

Updated: Oct 25, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.3K

Baricitinib for the treatment of atopic dermatitis

Amelia Melo1, Jose Manuel Carrascosa2, Tiago Torres1,3

  • 1Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.

The Journal of Dermatological Treatment
|August 11, 2021
PubMed

Insights

Baricitinib offers a new, effective treatment for moderate-to-severe atopic dermatitis (AD) by targeting the Janus kinase (JAK) pathway. Clinical trials show promising efficacy and a favorable safety profile for this JAK inhibitor in AD patients.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant patient and societal impact.
  • Current treatments present unmet needs, driving research for novel therapeutic agents.
  • Understanding the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway's role in AD pathogenesis is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of baricitinib, a selective JAK inhibitor, for treating atopic dermatitis.
  • To assess baricitinib's potential as a new therapeutic option for moderate-to-severe AD.

Main Methods:

  • Phase II and Phase III clinical trials were conducted to assess baricitinib's effectiveness and safety.
  • Baricitinib's selectivity for JAK1 and JAK2 was a key consideration in its development.

Main Results:

  • Clinical trials demonstrated encouraging efficacy of baricitinib in treating atopic dermatitis.
  • Baricitinib exhibited a favorable safety and tolerability profile in study participants.
  • The drug's mechanism involves blocking the JAK-STAT signaling pathway implicated in AD.

Conclusions:

  • Baricitinib represents a promising therapeutic advancement for moderate-to-severe atopic dermatitis.
  • The European Medicines Agency (EMA) approved baricitinib for adult patients requiring systemic therapy.
  • This approval expands treatment options for individuals suffering from this debilitating skin condition.
Keywords:
Atopic dermatitisJAK inhibitorsJAK/STATbaricitinib

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.4K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
250
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
245
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
278
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
483